

# 2009-2010 Report

*Building a Foundation for a Brighter Future*



Created by a nonpartisan act of Congress, the Reagan-Udall Foundation for the Food and Drug Administration is an independent 501(c)(3) not-for-profit organization that leads collaborations among the Food and Drug Administration (FDA), academic research institutions and industry to improve safety in regulated product evaluation and make their development more predictable and manageable.

Senator Michael B. Enzi (R-WY) and Senator Ted Kennedy (D-MA) championed the FDA Revitalization Act of 2007, which called for the Foundation's formation. Their goal was to demonstrate that a bipartisan Congress and public-private partnerships could advance FDA towards its mission to modernize product development, accelerate innovation and enhance product safety — ultimately improving America's public health.

---

*The Foundation was named for two federal leaders who battled incurable neurodegenerative diseases: President Ronald Reagan, who died of Alzheimer's complications, and Congressman Morris "Mo" Udall, a 14-term Democratic congressman from Arizona who battled Parkinson's disease.*

---

During 2009-2010, the Foundation's newly formed Board of Directors led efforts to secure critical funding, while ensuring autonomy from engaged parties, and began establishing the Foundation's infrastructure.

## 2009-2010 BOARD of DIRECTORS & LEADERSHIP

Chair: *Mark McClellan, MD, PhD, 18<sup>th</sup> Commissioner of the FDA*  
Vice Chair: *Ellen Sigal, PhD, Chair and Founder, Friends of Cancer Research*  
Secretary: *Kay Holcombe, Senior Vice President for Science Policy, Biotechnology Innovation Organization*  
Treasurer: *Georges Benjamin, MD, Executive Director, American Public Health Association*  
Director: *Helen Darling, President, National Business Group on Health*  
Director: *Michael Doyle, PhD, Manager of Regulatory Affairs, NxStage Medical*  
Director: *Sharon Levine, MD, Associate Executive Director, The Permanente Medical Group, Inc.*  
Director: *Garry Neil, MD, Corporate Vice President of Science and Technology, Johnson & Johnson*  
Director: *Phillip Sharp, PhD, Professor of Biology and Member, Koch Institute*  
Director: *Tadataka Yamada, MD, Executive Director, Global Health, Bill and Melinda Gates Foundation*  
Director: *Diana Zuckerman, PhD, President, National Center for Health Research*  
Ex officio: *Francis S. Collins, MD, PhD, Director, National Institutes of Health*  
Ex officio: *Margaret Hamburg, MD, Commissioner, Food and Drug Administration*  
Executive Director: *Jane Reese-Coulbourne*

**Building Infrastructure.** The Foundation appointed its first executive director, Jane Reese-Coulbourne, in 2010. It also instituted strict transparency and conflict of interest policies and procedures, which were posted in the Federal Register, and rigid financial policies to ensure the utmost integrity in all the Foundation's work.

**Building Programs.** From scratch, the founding Board of Directors — with input from FDA Commissioner Dr. Margaret Hamburg — navigated a multitude of focus areas to inform the Foundation’s program and resource development priorities.

With the help of a Bill and Melinda Gates Foundation grant, the Foundation began its first program in 2010, the **Critical Path to Tuberculosis Drug Regimens (CPTR)**, to accelerate the development and impact of new and markedly improved tuberculosis drug regimens to ultimately overcome obstacles to new drugs. This newly created consortium — comprised of the Gates Foundation, the Critical Path Institute and the TB Alliance — kicked off in March 2010.



**Building Opportunities.** The Foundation’s initial years of concentrated infrastructure-building and resource procurement positioned it for steady growth, success and achievement, as envisioned by its Congressional champions.

Please find the Reagan-Udall Foundation’s 990s forms and its Audit and Financial Reports via the following links:

- Audit and Financial Reports: <https://reaganudall.org/sites/default/files/2019-12/Reagan-Udall-Foundation-for-the-FDA-Financials-PDF.pdf>
- IRS Form 990 (2009): [https://reaganudall.org/sites/default/files/2019-12/RUF-09-990-Public%20Disclosure\\_0.pdf](https://reaganudall.org/sites/default/files/2019-12/RUF-09-990-Public%20Disclosure_0.pdf)
- IRS Form 990 (2010): <https://reaganudall.org/sites/default/files/2019-12/RUF-10-990-Public%20Disclosure.pdf>